- Article
NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice
- Aikaterini Kaloudi,
- Emmanouil Lymperis,
- Athina Giarika,
- Simone Dalm,
- Francesca Orlandi,
- Donato Barbato,
- Mattia Tedesco,
- Theodosia Maina,
- Marion De Jong and
- Berthold A. Nock
Background: The GRPR-antagonist-based radioligands [67/68Ga/111In/177Lu]NeoBOMB1 have shown excellent theragnostic profiles in preclinical prostate cancer models, while [68Ga]NeoBOMB1 effectively visualized prostate cancer lesions in patients. We wer...